Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction (CORAL)

22 de julho de 2026 atualizado por: Neurodawn Pharmaceutical Co., Ltd.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Clinical Trial of Y-6 Sublingual Tablets for the Treatment of Acute Perforator Artery Territory Infarction

The goal of this clinical trial is to learn if Y-6 sublingual tablets work to improve functional outcomes in patients with acute perforating artery infarction. It will also learn about the safety of Y-6 sublingual tablets.

The main questions it aims to answer are:

Does Y-6 sublingual tablets increase the proportion of participants who achieve a modified Rankin Scale (mRS) score of 0-1 at Day 90 after treatment? What medical problems do participants have when taking Y-6 sublingual tablets?

Researchers will compare different doses of Y-6 sublingual tablets and placebo to evaluate the effectiveness and safety of Y-6 sublingual tablets in patients with acute perforating artery infarction.

Participants will:

Take Y-6 sublingual tablets or placebo according to the assigned treatment regimen.

Visit the clinic for assessments of neurological function, functional outcomes, and safety during the study period.

Complete clinical assessments, including neurological examinations, laboratory tests, and other safety evaluations.

Be followed for functional outcomes and safety events after treatment.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

This is a multicenter, randomized, double-blind, placebo-controlled, seamless adaptive Phase II/III clinical trial to evaluate the efficacy and safety of Y-6 sublingual tablets in patients with acute perforating artery infarction. The study consists of two stages. In Stage 1, participants will be randomly assigned to receive high-dose Y-6 sublingual tablets (2 tablets, containing a total of 12 mg of borneol and 50 mg of cilostazol), low-dose Y-6 sublingual tablets (1 tablet containing 6 mg of borneol and 25 mg of cilostazol plus 1 matching placebo tablet), or placebo (2 matching placebo tablets), in addition to standard antiplatelet therapy with aspirin (100mg). The purpose of Stage 1 is to evaluate the efficacy and safety of different doses of Y-6 sublingual tablets and select the recommended dose for Stage 2 based on interim analyses reviewed by an independent data monitoring committee (IDMC). In Stage 2, participants will be randomly assigned to receive the selected dose of Y-6 sublingual tablets or placebo, in addition to concomitant aspirin therapy, to confirm the efficacy and safety of Y-6 sublingual tablets. Participants will receive study treatment and be followed for efficacy and safety outcomes, including functional outcomes, adverse events, bleeding events, and other safety assessments

Tipo de estudo

Intervencional

Inscrição (Estimado)

944

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100070
        • Beijing Tiantan Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  1. Male or female participants aged ≥18 and ≤80 years;
  2. Onset of stroke within 72 hours before the first administration of study treatment;
  3. Clinical symptoms and signs suggestive of an acute isolated perforating artery territory infarction (no cortical involvement, no multifocal involvement, NIHSS score between 4 and 15, and level of consciousness item 1a ≤1);
  4. Pre-stroke modified Rankin Scale (mRS) score ≤1 before the current stroke onset;
  5. Brain magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI) showing an isolated infarction lesion in the perforating artery territory (including the basal ganglia, internal capsule, thalamus, pons, etc.) with a diameter <30 mm, and meeting at least one of the following criteria:

    1. The infarct lesion involves at least 3 DWI axial slices;
    2. The maximum diameter of the lesion on DWI is ≥15 mm;
    3. The DWI lesion is connected to the ventral surface of the pons, located near the midline, unilateral, and does not cross the midline;
  6. No severe stenosis of the parent artery supplying the infarct territory (severe stenosis defined as >70% stenosis on magnetic resonance angiography [MRA], or >50% stenosis on computed tomography angiography [CTA] or digital subtraction angiography [DSA]);
  7. The participant or legally authorized representative voluntarily signs the informed consent form approved by the ethics committee.

Exclusion Criteria:

  1. Known allergy to any component of the investigational product or its excipients;
  2. Ischemic stroke caused by large artery atherosclerosis, cardioembolism, arterial dissection, or vasculitis identified at screening;
  3. History of intracranial hemorrhagic diseases within 3 months prior to screening, including intracerebral hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma;
  4. History of other active or major neurological diseases, including recurrent seizures, intracranial tumors, vascular malformations (including arteriovenous malformations, arterial malformations, cavernous malformations), untreated aneurysms >3 mm in diameter, etc.;
  5. History of congestive heart failure, or acute myocardial infarction within 3 months prior to screening, or severe cardiac dysfunction (NYHA class III-IV);
  6. Significant head trauma, intracranial or spinal surgery, or severe physical trauma within 4 weeks prior to screening; major surgery within 3 months prior to screening; or planned endovascular treatment during the study period;
  7. Severe hepatic or renal dysfunction at screening, or meeting any of the following criteria:

    1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN);
    2. Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m² (calculated using the CKD-EPI equation based on serum creatinine; see Appendix 4);
  8. Coagulation disorders, bleeding tendency, or active systemic bleeding at screening, including but not limited to:

    1. Prothrombin time >1.5 × ULN;
    2. Platelet count <100 × 10⁹/L;
    3. Hemophilia, capillary fragility disorders, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.;
  9. Persistent systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite antihypertensive treatment;
  10. Known acute gastrointestinal ulcer;
  11. History of asthma induced by salicylates or salicylate-containing substances (especially non-steroidal anti-inflammatory drugs [NSAIDs]);
  12. Continuous use of dual antiplatelet therapy within 5 days prior to screening, or administration of loading doses of clopidogrel (300 mg) or ticagrelor (180 mg) after current stroke onset and before screening, or use of antiplatelet agents other than aspirin, cilostazol, clopidogrel, or ticagrelor after current stroke onset and before screening;
  13. Received intravenous thrombolysis, thrombectomy, other endovascular treatment, or bridging therapy after current stroke onset; or received anticoagulants, batroxobin, defibrase, snake venom-derived preparations, or lumbrokinase therapy;
  14. Presence of a clear indication for anticoagulation (suspected cardioembolic stroke, such as atrial fibrillation, known prosthetic heart valve, atrial myxoma, endocarditis, etc.) or a clear indication for dual antiplatelet therapy (such as recent coronary artery stenting or intracranial artery stenting);
  15. Expected need for long-term use of NSAIDs other than the study medication;
  16. Life expectancy ≤12 months;
  17. Participation in any other interventional clinical trial within 3 months prior to screening or current participation in another clinical trial;
  18. Male participants (or their partners) or female participants who plan to conceive during the study period, or participants unwilling to use one or more non-drug contraceptive methods (such as complete abstinence, condoms, sterilization, etc.) throughout the study period;
  19. Pregnant or breastfeeding women;
  20. Any other condition considered by the investigator to potentially affect compliance or make the participant unsuitable for participation in this study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Y-6 tablet
twice daily for 90 consecutive days
Y-6 sublingual tablets (in accordance with the optimal dose established in stage 1) taken sublingually twice daily for 90 consecutive days.
Comparador de Placebo: Placebo
twice daily for 90 consecutive days
Placebo (in accordance with the optimal dose established in stage 1) taken sublingually twice daily for 90 consecutive days.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Proportion of participants achieving a modified Rankin Scale (mRS) score ≤1 after treatment
Prazo: Day 90(+7 days)
The scale ranges from 0 to 6, where a score of 0 indicates no symptoms and a score of 6 indicates death. Higher mRS scores represent greater disability.
Day 90(+7 days)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Distribution of mRS scores after treatment
Prazo: Day 90(+7 days)
The scale ranges from 0 to 6, where a score of 0 indicates no symptoms and a score of 6 indicates death. Higher mRS scores represent greater disability.
Day 90(+7 days)
Proportion of participants with stroke-related disability after treatment
Prazo: Day90 (+7 days)
Stroke disability is defined as disability (modified Rankin Scale [mRS] score of 3-5), major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and vascular death, and all-cause mortality.
Day90 (+7 days)
Change from baseline in NIHSS (National Institutes of Health Stroke Scale) scores at each assessment time point
Prazo: Day90 (+7 days)
The NIHSS total score ranges from 0 to 42, with higher scores indicating worse neurological outcomes.
Day90 (+7 days)
Proportion of participants achieving a Barthel Index score ≥95 after treatment
Prazo: Day 90 (+7 days)
The Barthel Index (BI) is a measure of activities of daily living, with scores ranging from 0 to 100. Higher scores indicate greater independence, while lower scores indicate greater dependence on assistance for daily activities.
Day 90 (+7 days)
Proportion of participants with early neurological deterioration after treatment
Prazo: 72 hours (±12 hours) after treatment、Day 7 (±1 day)
Early neurological deterioration means within 7 days after stroke attack, an increase in NIHSS of ≥2 points or an increase in hemiparesis of ≥1 point or an increase in impaired consciousness of ≥1 point from baseline and excluding progression of disease due to intracranial hemorrhage by examination of cranial CT or MRI and exacerbation of disease due to other non-stroke causes, such as cardiac insufficiency, hepatic insufficiency, renal insufficiency, etc.
72 hours (±12 hours) after treatment、Day 7 (±1 day)
Proportion of participants with ischemic stroke after treatment
Prazo: Day90 (+7 days)
Day90 (+7 days)
Incidence of moderate and severe bleeding events after treatment
Prazo: Day 30 (±3 days)、Day 90 (+7 days)
Bleeding events will be classified according to the GUSTO bleeding criteria. Severe or life-threatening bleeding is defined as intracerebral hemorrhage or bleeding resulting in substantial hemodynamic compromise requiring treatment. Moderate bleeding is defined as bleeding requiring blood transfusion. Minor bleeding is defined as other bleeding events not requiring transfusion or causing hemodynamic compromise.
Day 30 (±3 days)、Day 90 (+7 days)
Incidence of intracranial hemorrhage after treatment
Prazo: Day 30 (±3 days)、Day 90 (+7 days)
Day 30 (±3 days)、Day 90 (+7 days)
Incidence of any bleeding events after treatment
Prazo: Day 30 (±3 days)、Day 90 (+7 days)
Day 30 (±3 days)、Day 90 (+7 days)
All-cause Mortality after treatment
Prazo: Day 30 (±3 days)、Day 90 (+7 days)
Day 30 (±3 days)、Day 90 (+7 days)
Incidence of platelet count ≤100 × 10⁹/L after treatment
Prazo: Day 30 (±3 days)、Day 90(+7 days)
Day 30 (±3 days)、Day 90(+7 days)
Incidence of new-onset moderate-to-severe headache after treatment
Prazo: Day 30 (±3 days)、Day 90 (+7 days)
Headache severity will be assessed using the 11-point Numerical Rating Scale (11-NRS). The scale ranging from 0 to 10, where 0 indicates no headache and 10 indicates the worst imaginable headache. Higher scores indicate greater headache severity.
Day 30 (±3 days)、Day 90 (+7 days)
Incidence and severity of adverse events after treatment
Prazo: Day 90 (+7days)
Day 90 (+7days)
The Incidence of subject getting abnormal results of physical examinations after treatment
Prazo: Day 90 (+7days)
Day 90 (+7days)
The Incidence of subject getting abnormal results of vital signs after treatment
Prazo: Day 90 (+7days)
Day 90 (+7days)
The Incidence of subject getting abnormal results of laboratory tests after treatment
Prazo: Day 90 (+7days)
Day 90 (+7days)
The Incidence of subject getting abnormal results of 12-lead electrocardiograms after treatment
Prazo: Day 90 (+7 days)
Day 90 (+7 days)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Distribution of mRS scores after treatment
Prazo: Day 180 (±10 days)、Day 360 (±15 days)
The scale ranges from 0 to 6, where a score of 0 indicates no symptoms and a score of 6 indicates death. Higher mRS scores represent greater disability.
Day 180 (±10 days)、Day 360 (±15 days)
Proportion of participants with stroke-related disability after treatment
Prazo: Day 180 (±10 days)、Day 360 (±15 days)
Stroke disability is defined as disability (modified Rankin Scale [mRS] score of 3-5), major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and vascular death, and all-cause mortality.
Day 180 (±10 days)、Day 360 (±15 days)
Proportion of participants achieving a Barthel Index score ≥95 after treatment
Prazo: Day 180 (±10 days)、Day 360 (±15 days)
The Barthel Index (BI) is a measure of activities of daily living, with scores ranging from 0 to 100. Higher scores indicate greater independence, while lower scores indicate greater dependence on assistance for daily activities.
Day 180 (±10 days)、Day 360 (±15 days)
Proportion of participants with ischemic stroke after treatment
Prazo: Day 180 (±10 days)、Day 360 (±15 days)
Day 180 (±10 days)、Day 360 (±15 days)
Change from baseline in structural brain imaging parameters assessed by 3D-T1-weighted MRI
Prazo: Day 90(+7 days)
Day 90(+7 days)
Change from baseline in diffusion tensor imaging (DTI) parameters
Prazo: Day 90(+7 days)
Day 90(+7 days)
Change from baseline in functional MRI parameters assessed by BOLD-fMRI
Prazo: Day 90(+7 days)
Day 90(+7 days)
Change from baseline in cerebral hemodynamic parameters
Prazo: Day 180 (±10 days)、Day 360 (±15 days)
Day 180 (±10 days)、Day 360 (±15 days)
Changes from baseline in blood biomarker phosphodiesterase 3A (PDE3A) levels
Prazo: Day 90(+7 days)
Day 90(+7 days)
Change from baseline in Montreal Cognitive Assessment (MoCA) score
Prazo: Day 180 (±10 days) 、Day 360 (±15 days)
Day 180 (±10 days) 、Day 360 (±15 days)
Change from baseline in Digit Span Test performance
Prazo: Day 180 (±10 days) 、Day 360 (±15 days)
Day 180 (±10 days) 、Day 360 (±15 days)
Change from baseline in Rey Auditory Verbal Learning Test (RAVLT) performance
Prazo: Day 180 (±10 days) 、Day 360 (±15 days)
Day 180 (±10 days) 、Day 360 (±15 days)
Change from baseline in Color Trail Test performance
Prazo: Day 180 (±10 days)、Day 360 (±15 days)
Day 180 (±10 days)、Day 360 (±15 days)
Change from baseline in Stroop Color-Word Test performance
Prazo: Day 180 (±10 days)、Day 360 (±15 days)
Day 180 (±10 days)、Day 360 (±15 days)
Change from baseline in Functional Activities Questionnaire (FAQ) score
Prazo: Day 180 (±10 days) 、Day 360 (±15 days)
Day 180 (±10 days) 、Day 360 (±15 days)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

31 de agosto de 2026

Conclusão Primária (Estimado)

28 de fevereiro de 2028

Conclusão do estudo (Estimado)

31 de julho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

10 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de julho de 2026

Primeira postagem (Real)

23 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

23 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • Y-6-LC-05

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever